论文部分内容阅读
FDA批准艾伯维突破性抗癌药Imbruvica一线治疗CLL FDA批准美国生物技术巨头艾伯维的突破性抗癌药Imbruvica(ibrutinib)用于慢性淋巴细胞白血病(CLL)患者的一线治疗。此次批准,首次为CLL群体提供了一种无化疗(chemotherapy-free)的一线治疗选择,同时也使得Imbruvica在美国的治疗适应证达到了5个之多。FDA批准辉瑞Crizotinib治疗ROS1阳性NSCLC辉瑞的Crizotinib 3月11日获FDA批准用于治疗ROS1阳性的
FDA Approves First-line Treatment of Imbruvica, a Breakthrough Cancer Drug By Alibaba CLL FDA approves first-line treatment of patients with chronic lymphocytic leukemia (CLL) with Imbruvica (ibrutinib), a breakthrough anti-cancer drug from the US biotech giant Alberwein. This approval, for the first time, provides a first-line chemotherapy-free option for the CLL population and also brings as many as five indications of treatment to Imbruvica in the United States. FDA Approves Crizotinib for Pfizer Crizotinib for ROS1-Positive NSCLC Pfizer Crizotinib Approved by the FDA on March 11 for ROS1-Positive